Pharmacoeconomic analysis of topical treatments for tinea infections.
The purpose of this study was to perform a government-perspective economic analysis of the most widely used topical creams [namely, ciclopirox (CIC), clotrimazole (CLO), ketoconazole (KET), miconazole (MIC), and terbinafine (TER)], for the treatment of 2 types of dermatophyte skin infections: dermatophytosis major (excluding onychomycosis) and dermatophytosis minor. A 3-phase approach was used. In phase I, experts were assembled to identify the standard approach for management of fungal infections and a decision tree was constructed to model the process; in phase II, meta-analysis was used to determine success, failure, and relapse rates; and in phase III, economic analyses were performed including cost of regimen, total expected cost and cost-effectiveness analysis. Sensitivity analyses (robustness analyses) were also performed in phase III. It was found that while TER was successful following 1 week of administration for minor infections and after 2 weeks for major infections, duration of drug treatment was usually twice that time. Other comparators (CIC, CLO, KET and MIC) took 4 weeks to achieve a successful outcome. In addition, an extra 2 weeks were often needed to clear both types of infections because the comparators are fungistatic, whereas TER is fungicidal. In the total expected cost analysis, TER had the lowest overall cost of treating patients for both infection categories. It was also responsible for the highest number of disease-free days and, consequently, the lowest cost per disease-free day. Sensitivity analyses confirmed that TER was the most cost-effective topical agent for treating dermatophytosis major (excluding onychomycosis) and dermatophytosis minor.
Shear
N H
NH
Faculty of Medicine, Department of Medicine, Sunnybrook Health Science Center, Toronto, Ontario, Canada.
Einarson
T R
TR
Arikian
S R
SR
Doyle
J J
JJ
D000287:Administration, Topical; D000328:Adult; D000935:Antifungal Agents / Q000191:economics* / Q000627:therapeutic use*; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D003022:Clotrimazole / Q000627:therapeutic use; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D011728:Pyridones / Q000191:economics* / Q000627:therapeutic use*; D014005:Tinea / Q000188:drug therapy* / Q000191:economics*; D016896:Treatment Outcome